224 related articles for article (PubMed ID: 19178153)
1. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
[TBL] [Abstract][Full Text] [Related]
2. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
3. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
4. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
Kobayashi M; Nakahara K; Seki T; Miki S; Kawauchi S; Suyama A; Wakasa-Morimoto C; Kodama M; Endoh T; Oosugi E; Matsushita Y; Murai H; Fujishita T; Yoshinaga T; Garvey E; Foster S; Underwood M; Johns B; Sato A; Fujiwara T
Antiviral Res; 2008 Nov; 80(2):213-22. PubMed ID: 18625269
[TBL] [Abstract][Full Text] [Related]
5. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
6. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
7. Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor.
Brigo A; Lee KW; Fogolari F; Mustata GI; Briggs JM
Proteins; 2005 Jun; 59(4):723-41. PubMed ID: 15815973
[TBL] [Abstract][Full Text] [Related]
8. Resistance to novel drug classes.
Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
[TBL] [Abstract][Full Text] [Related]
9. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
10. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.
Deprez E; Barbe S; Kolaski M; Leh H; Zouhiri F; Auclair C; Brochon JC; Le Bret M; Mouscadet JF
Mol Pharmacol; 2004 Jan; 65(1):85-98. PubMed ID: 14722240
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
13. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.
Witmer M; Danovich R
Methods; 2009 Apr; 47(4):277-82. PubMed ID: 19286458
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
[TBL] [Abstract][Full Text] [Related]
15. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
17. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Grobler JA; Stillmock K; Hu B; Witmer M; Felock P; Espeseth AS; Wolfe A; Egbertson M; Bourgeois M; Melamed J; Wai JS; Young S; Vacca J; Hazuda DJ
Proc Natl Acad Sci U S A; 2002 May; 99(10):6661-6. PubMed ID: 11997448
[TBL] [Abstract][Full Text] [Related]
18. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
19. Resistance to HIV integrase inhibitors.
Mesplède T; Quashie PK; Wainberg MA
Curr Opin HIV AIDS; 2012 Sep; 7(5):401-8. PubMed ID: 22789986
[TBL] [Abstract][Full Text] [Related]
20. A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
De Luca L; Barreca ML; Ferro S; Iraci N; Michiels M; Christ F; Debyser Z; Witvrouw M; Chimirri A
Bioorg Med Chem Lett; 2008 May; 18(9):2891-5. PubMed ID: 18417342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]